We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest close session, CVS Health (CVS - Free Report) was up +1.97% at $92.17. The stock exceeded the S&P 500, which registered a gain of 0.33% for the day. Elsewhere, the Dow gained 1.08%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the drugstore chain and pharmacy benefits manager had lost 1.45% over the past month, lagging the Medical sector's loss of 0.15% and the S&P 500's gain of 1.41%.
The upcoming earnings release of CVS Health will be of great interest to investors. The company's earnings report is expected on November 4, 2026. It is anticipated that the company will report an EPS of $1.62, marking a 1.25% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $105.04 billion, indicating a 2.11% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.02 per share and revenue of $418.17 billion, indicating changes of +18.81% and +4.01%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. CVS Health is currently a Zacks Rank #3 (Hold).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 11.26. This expresses a discount compared to the average Forward P/E of 17.87 of its industry.
Also, we should mention that CVS has a PEG ratio of 0.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.72 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider
In the latest close session, CVS Health (CVS - Free Report) was up +1.97% at $92.17. The stock exceeded the S&P 500, which registered a gain of 0.33% for the day. Elsewhere, the Dow gained 1.08%, while the tech-heavy Nasdaq added 0.08%.
Heading into today, shares of the drugstore chain and pharmacy benefits manager had lost 1.45% over the past month, lagging the Medical sector's loss of 0.15% and the S&P 500's gain of 1.41%.
The upcoming earnings release of CVS Health will be of great interest to investors. The company's earnings report is expected on November 4, 2026. It is anticipated that the company will report an EPS of $1.62, marking a 1.25% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $105.04 billion, indicating a 2.11% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.02 per share and revenue of $418.17 billion, indicating changes of +18.81% and +4.01%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. CVS Health is currently a Zacks Rank #3 (Hold).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 11.26. This expresses a discount compared to the average Forward P/E of 17.87 of its industry.
Also, we should mention that CVS has a PEG ratio of 0.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.72 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.